Plasma protein binding: from discovery to development.

The importance of plasma protein binding (PPB) in modulating the effective drug concentration at pharmacological target sites has been the topic of significant discussion and debate amongst drug development groups over the past few decades. Free drug theory, which states that in absence of energy-dependent processes, after steady state equilibrium has been attained, free drug concentration in plasma is equal to free drug concentration at the pharmacologic target receptor(s) in tissues, has been used to explain pharmacokinetics/pharmacodynamics relationships in a large number of cases. Any sudden increase in free concentration of a drug could potentially cause toxicity and may need dose adjustment. Free drug concentration is also helpful to estimate the effective concentration of drugs that potentially can precipitate metabolism (or transporter)-related drug-drug interactions. Disease models are extensively validated in animals to progress a compound into development. Unbound drug concentration, and therefore PPB information across species is very informative in establishing safety margins and guiding selection of First in Human (FIH) dose and human efficacious dose. The scope of this review is to give an overview of reported role of PPB in several therapeutic areas, highlight cases where PPB changes are clinically relevant, and provide drug metabolism and pharmacokinetics recommendations in discovery and development settings.

[1]  A. Petros,et al.  Discovery and structure-activity relationship of antagonists of B-cell lymphoma 2 family proteins with chemopotentiation activity in vitro and in vivo. , 2006, Journal of medicinal chemistry.

[2]  J. Verweij,et al.  The (ir)relevance of plasma protein binding of anticancer drugs. , 2001, The Netherlands journal of medicine.

[3]  R. Chopra,et al.  3,5-Dioxopyrazolidines, Novel Inhibitors of UDP-N- Acetylenolpyruvylglucosamine Reductase (MurB) with Activity against Gram-Positive Bacteria , 2006, Antimicrobial Agents and Chemotherapy.

[4]  M. Hammarlund-Udenaes.  Active-site concentrations of chemicals - are they a better predictor of effect than plasma/organ/tissue concentrations? , 2010, Basic & clinical pharmacology & toxicology.

[5]  R Scott Obach,et al.  Metabolites in safety testing (MIST): considerations of mechanisms of toxicity with dose, abundance, and duration of treatment. , 2009, Chemical research in toxicology.

[6]  Y. Sugiyama,et al.  Marked Strain Differences in the Pharmacokinetics of an α4β1 Integrin Antagonist, 4-[1-[3-Chloro-4-[N-(2-methylphenyl)-ureido]phenylacetyl]-(4S)-fluoro-(2S)-pyrrolidine-2-yl]-methoxybenzoic Acid (D01-4582), in Sprague-Dawley Rats Are Associated with Albumin Genetic Polymorphism , 2007, Journal of Pharmacology and Experimental Therapeutics.

[7]  Huidi Jiang,et al.  Stereoselective protein binding of tetrahydropalmatine enantiomers in human plasma, HSA, and AGP, but not in rat plasma. , 2009, Chirality.

[8]  P. Murumkar,et al.  Current perspective of TACE inhibitors: a review. , 2009, Bioorganic & medicinal chemistry.

[9]  Margareta Hammarlund-Udenaes,et al.  Blood–Brain Barrier Transport Helps to Explain Discrepancies in In Vivo Potency between Oxycodone and Morphine , 2008, Anesthesiology.

[10]  I. E. Smith,et al.  Pyridyl-2,5-diketopiperazines as potent, selective, and orally bioavailable oxytocin antagonists: synthesis, pharmacokinetics, and in vivo potency. , 2006, Journal of medicinal chemistry.

[11]  David W. Johnson,et al.  Mycophenolic acid pharmacokinetics and related outcomes early after renal transplant. , 2005, British journal of clinical pharmacology.

[12]  G. Tucker,et al.  Prediction of plasma protein binding displacement and its implications for quantitative assessment of metabolic drug-drug interactions from in vitro data. , 2006, Journal of pharmaceutical sciences.

[13]  T. Buclin,et al.  Prediction of free imatinib concentrations based on total plasma concentrations in patients with gastrointestinal stromal tumours. , 2013, British journal of clinical pharmacology.

[14]  C. Kohlsdorfer,et al.  High-throughput determination of the free fraction of drugs strongly bound to plasma proteins. , 2004, Journal of pharmaceutical sciences.

[15]  M Paul Gleeson,et al.  Plasma protein binding affinity and its relationship to molecular structure: an in-silico analysis. , 2007, Journal of medicinal chemistry.

[16]  Xingrong Liu,et al.  Do we need to optimize plasma protein and tissue binding in drug discovery? , 2011, Current topics in medicinal chemistry.

[17]  Y. Sugiyama,et al.  Altered pharmacokinetics of a novel anticancer drug, UCN-01, caused by specific high affinity binding to alpha1-acid glycoprotein in humans. , 1999, Cancer research.

[18]  C. Ardiet,et al.  Pharmacokinetics of alkylating agents. , 1993, Cancer surveys.

[19]  J. Feely,et al.  A comparison of drug protein binding and alpha 1-acid glycoprotein concentration in Chinese and Caucasians. , 1991, British journal of clinical pharmacology.

[20]  Ann D. Kwong,et al.  VX-950, a Novel Hepatitis C Virus (HCV) NS3-4A Protease Inhibitor, Exhibits Potent Antiviral Activities in HCV Replicon Cells , 2006, Antimicrobial Agents and Chemotherapy.

[21]  C. Staatz,et al.  Clinical Pharmacokinetics and Pharmacodynamics of Mycophenolate in Solid Organ Transplant Recipients , 2007, Clinical pharmacokinetics.

[22]  P. McNamara,et al.  GF120918, a P-Glycoprotein Modulator, Increases the Concentration of Unbound Amprenavir in the Central Nervous System in Rats , 2002, Antimicrobial Agents and Chemotherapy.

[23]  S. Zeng,et al.  Enantioselective plasma protein binding of propafenone: mechanism, drug interaction, and species difference. , 2009, Chirality.

[24]  Juan J. Marugan,et al.  Original articleNovel potent and selective αvβ3/αvβ5 integrin dual antagonists with reduced binding affinity for human serum albumin , 2006 .

[25]  B. Fichtl,et al.  Binding of drugs to tissues. , 1983, Drug metabolism reviews.

[26]  Don Walker,et al.  A holistic strategy for characterizing the safety of metabolites through drug discovery and development. , 2009, Chemical research in toxicology.

[27]  J. Pedraz,et al.  Pharmacokinetic-pharmacodynamic modeling: time-dependent protein binding--an alternative interpretation of clockwise and counterclockwise hysteresis. , 1992, Journal of pharmaceutical sciences.

[28]  Y. Sugiyama,et al.  Prediction of the disposition ofβ-lactam antibiotics in humans from pharmacokinetic parameters in animals , 1984, Journal of Pharmacokinetics and Biopharmaceutics.

[29]  D. Breilh,et al.  Pharmacokinetics and lung concentrations of ertapenem in patients with ventilator-associated pneumonia , 2006, Intensive Care Medicine.

[30]  N. D. Kim,et al.  Pharmacokinetics of drugs in blood. VII: Unusual distribution and blood storage effect of vancomycin. , 1992, Biopharmaceutics & drug disposition.

[31]  J. Bischoff,et al.  3-Amino-1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazoles: a new class of CDK2 inhibitors. , 2006, Bioorganic & medicinal chemistry letters.

[32]  Xi Chen,et al.  THE IMPACT OF P-GLYCOPROTEIN ON THE DISPOSITION OF DRUGS TARGETED FOR INDICATIONS OF THE CENTRAL NERVOUS SYSTEM: EVALUATION USING THE MDR1A/1B KNOCKOUT MOUSE MODEL , 2005, Drug Metabolism and Disposition.

[33]  C. Bertucci,et al.  Species-dependent stereoselective drug binding to albumin: a circular dichroism study. , 2008, Chirality.

[34]  M. Albrecht,et al.  Update on the pharmacokinetic aspects of antiretroviral agents: implications in therapeutic drug monitoring. , 2006, Current pharmaceutical design.

[35]  A. McLachlan,et al.  Factors affecting variability in distribution of tacrolimus in liver transplant recipients. , 2003, British journal of clinical pharmacology.

[36]  C. Fausel.  Targeted Chronic Myeloid Leukemia Therapy: Seeking a Cure , 2007, Journal of managed care pharmacy : JMCP.

[37]  D. Ho,et al.  A preliminary study of ritonavir, an inhibitor of HIV-1 protease, to treat HIV-1 infection. , 1995, The New England journal of medicine.

[38]  J. Bilello,et al.  Reduction of the in vitro activity of A77003, an inhibitor of human immunodeficiency virus protease, by human serum alpha 1 acid glycoprotein. , 1995, The Journal of infectious diseases.

[39]  Hartmut Derendorf,et al.  Issues in Pharmacokinetics and Pharmacodynamics of Anti-Infective Agents: Kill Curves versus MIC , 2004, Antimicrobial Agents and Chemotherapy.

[40]  Yuichi Sugiyama,et al.  Prediction of the volumes of distribution of basic drugs in humans based on data from animals , 1984, Journal of Pharmacokinetics and Biopharmaceutics.

[41]  G. Wilkinson.  Plasma and tissue binding considerations in drug disposition. , 1983, Drug metabolism reviews.

[42]  L. Christensen,et al.  Drug Interactions with Oral Sulphonylurea Hypoglycaemic Drugs , 2012, Drugs.

[43]  W. Rapeport,et al.  Plasma protein-binding and CSF concentrations of valproic acid in man following acute oral dosing. , 1983, British journal of clinical pharmacology.

[44]  Joseph L Duffy,et al.  Discovery of potent and selective orally bioavailable beta-substituted phenylalanine derived dipeptidyl peptidase IV inhibitors. , 2005, Bioorganic & medicinal chemistry letters.

[45]  N. Lenn,et al.  Clinical utility of unbound antiepileptic drug blood levels in the management of epilepsy , 1992, Neurology.

[46]  G. Wilkinson,et al.  Differences in plasma binding of drugs between Caucasians and Chinese subjects , 1990, Clinical pharmacology and therapeutics.

[47]  D. Haas,et al.  Steady‐state pharmacokinetics of indinavir in cerebrospinal fluid and plasma among adults with human immunodeficiency virus type 1 infection , 2000, Clinical pharmacology and therapeutics.

[48]  Xin Xu,et al.  In Vitro–In Vivo Correlation on Delivery of Drug Candidates to Articular Cartilage , 2008, Pharmaceutical Research.

[49]  M. Burnier,et al.  Tasosartan, enoltasosartan, and angiotensin II receptor blockade: the confounding role of protein binding. , 2000, The Journal of pharmacology and experimental therapeutics.

[50]  G. Trainor,et al.  The importance of plasma protein binding in drug discovery , 2007, Expert opinion on drug discovery.

[51]  Devane Cl.  Clinical significance of drug binding, protein binding, and binding displacement drug interactions. , 2002 .

[52]  L. Berezhkovskiy.  On the influence of protein binding on pharmacological activity of drugs. , 2010, Journal of pharmaceutical sciences.

[53]  M. Zucchetti,et al.  α1 Acid Glycoprotein Binds to Imatinib (STI571) and Substantially Alters Its Pharmacokinetics in Chronic Myeloid Leukemia Patients , 2003 .

[54]  L. Dubé,et al.  Comparison of the erythrocyte partitioning method with two classical methods for estimating free drug fraction in plasma. , 1984, Biopharmaceutics & drug disposition.

[55]  M. Hidalgo,et al.  Binding of gefitinib, an inhibitor of epidermal growth factor receptor-tyrosine kinase, to plasma proteins and blood cells: in vitro and in cancer patients , 2006, Investigational New Drugs.

[56]  G. Levy.  Effects of plasma protein binding of drugs on duration and intensity of pharmacological activity. , 1976, Journal of pharmaceutical sciences.

[57]  D. Denson,et al.  Differential effect of plasma protein binding of bupivacaine on its in vivo transfer into the brain and salivary gland of rats. , 1986, The Journal of pharmacology and experimental therapeutics.

[58]  T. Gilmer,et al.  A simple method for predicting serum protein binding of compounds from IC(50) shift analysis for in vitro assays. , 2004, Bioorganic & medicinal chemistry letters.

[59]  Edward H. Kerns,et al.  The effect of plasma protein binding on in vivo efficacy: misconceptions in drug discovery , 2010, Nature Reviews Drug Discovery.

[60]  L. J. Wilson,et al.  Simultaneous determination of enantioselective plasma protein binding of aminohydantoins by ultrafiltration and chiral high-performance liquid chromatography. , 1999, Journal of chromatography. B, Biomedical sciences and applications.

[61]  L. Sansom,et al.  What is the True Clinical Significance of Plasma Protein Binding Displacement Interactions? , 1995, Drug safety.

[62]  G. Wagner,et al.  A free lignocaine index as a guide to unbound drug concentration. , 1985, British journal of clinical pharmacology.

[63]  G R Wilkinson,et al.  Brain uptake of benzodiazepines: effects of lipophilicity and plasma protein binding. , 1988, The Journal of pharmacology and experimental therapeutics.

[64]  T. Nakagawa,et al.  High-performance frontal analysis for drug-protein binding study. , 1999, Journal of pharmaceutical and biomedical analysis.

[65]  D. Selley,et al.  Pharmacokinetics and Pharmacodynamics of Seven Opioids in P-Glycoprotein-Competent Mice: Assessment of Unbound Brain EC50,u and Correlation of in Vitro, Preclinical, and Clinical Data , 2007, Journal of Pharmacology and Experimental Therapeutics.

[66]  E. Suárez,et al.  Resistance to atracurium in rats with experimental inflammation: role of protein binchng , 1995, Acta anaesthesiologica Scandinavica.

[67]  G. Trainor,et al.  Receptor Occupancy of Nonpeptide Corticotropin-Releasing Factor 1 Antagonist DMP696: Correlation with Drug Exposure and Anxiolytic Efficacy , 2003, Journal of Pharmacology and Experimental Therapeutics.

[68]  J. Leonard,et al.  Human serum alpha 1 acid glycoprotein reduces uptake, intracellular concentration, and antiviral activity of A-80987, an inhibitor of the human immunodeficiency virus type 1 protease , 1996, Antimicrobial agents and chemotherapy.

[69]  P. Clevenbergh,et al.  Improving HIV infection management using antiretroviral plasma drug levels monitoring: a clinician's point of view. , 2004, Current HIV research.

[70]  B. Fichtl,et al.  Tissue Binding versus Plasma Binding of Drugs: General Principles and Pharmacokinetic Consequences , 1991 .

[71]  Felix Kratz,et al.  Albumin as a drug carrier: design of prodrugs, drug conjugates and nanoparticles. , 2008, Journal of controlled release : official journal of the Controlled Release Society.

[72]  Scott A. Erickson,et al.  Discovery and optimization of anthranilic acid sulfonamides as inhibitors of methionine aminopeptidase-2: a structural basis for the reduction of albumin binding. , 2006, Journal of medicinal chemistry.

[73]  J. K. Faulkner,et al.  Pharmacokinetics and tissue penetration of fluconazole in humans. , 1990, Reviews of infectious diseases.

[74]  David M. Shackleford,et al.  Stereoselective Hepatic Disposition of Model Diastereomeric Acyl Glucuronides , 2004, Journal of Pharmacokinetics and Pharmacodynamics.

[75]  H. Mitsuya,et al.  Protein binding of human immunodeficiency virus protease inhibitor KNI-272 and alteration of its in vitro antiretroviral activity in the presence of high concentrations of proteins , 1994, Antimicrobial Agents and Chemotherapy.

[76]  P. Murumkar,et al.  Studies on novel 2-imidazolidinones and tetrahydropyrimidin-2(1H)-ones as potential TACE inhibitors: design, synthesis, molecular modeling, and preliminary biological evaluation. , 2009, Bioorganic & medicinal chemistry.

[77]  K. Stoeckel,et al.  Pharmacokinetics of ceftriaxone in patients with renal and liver insufficiency and correlations with a physiologic nonlinear protein binding model. , 1984, The American journal of medicine.

[78]  L. Jia,et al.  LC-MS/MS assay and dog pharmacokinetics of the dimeric pyrrolobenzodiazepine SJG-136 (NSC 694501). , 2006, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

[79]  H. Boxenbaum.  Comparative pharmacokinetics of benzodiazepines in dog and man , 1982, Journal of Pharmacokinetics and Biopharmaceutics.

[80]  R Scott Obach,et al.  SEEING THROUGH THE MIST: ABUNDANCE VERSUS PERCENTAGE. COMMENTARY ON METABOLITES IN SAFETY TESTING , 2005, Drug Metabolism and Disposition.

[81]  J. Lin,et al.  Dose-dependent pharmacokinetics of diflunisal in rats: dual effects of protein binding and metabolism. , 1985, The Journal of pharmacology and experimental therapeutics.

[82]  J. McElnay,et al.  Protein Binding Displacement Interactions and their Clinical Importance , 1983, Drugs.

[83]  U. Bredberg,et al.  Methodologies to assess brain drug delivery in lead optimization. , 2009, Current topics in medicinal chemistry.

[84]  S. Khoo,et al.  Intra-individual variability in lopinavir plasma trough concentrations supports therapeutic drug monitoring. , 2003, AIDS.

[85]  Craig S Donald,et al.  Design of a potent, soluble glucokinase activator with excellent in vivo efficacy. , 2006, Bioorganic & medicinal chemistry letters.

[86]  M. Rudek,et al.  Plasma protein binding of sorafenib, a multi kinase inhibitor: in vitro and in cancer patients , 2012, Investigational New Drugs.

[87]  S. Bryson,et al.  The influence of protein binding on disopyramide clearance , 2004, European Journal of Clinical Pharmacology.

[88]  Jiunn H. Lin,et al.  CSF as a surrogate for assessing CNS exposure: an industrial perspective. , 2008, Current drug metabolism.

[89]  Ferenc Zsila,et al.  Determination of human serum alpha1-acid glycoprotein and albumin binding of various marketed and preclinical kinase inhibitors. , 2009, Current medicinal chemistry.

[90]  J. Mackichan.  Protein Binding Drug Displacement Interactions , 1989, Clinical pharmacokinetics.

[91]  B. Gidal,et al.  Apparent Valproic Acid Neurotoxicity in a Hypoalbuminemic Patient , 1993, The Annals of pharmacotherapy.

[92]  P. Montravers,et al.  Pharmacokinetics of antibiotics or antifungal drugs in intensive care units , 2009, Current infectious disease reports.

[93]  S. Apparsundaram,et al.  Unbound Brain Concentration Determines Receptor Occupancy: A Correlation of Drug Concentration and Brain Serotonin and Dopamine Reuptake Transporter Occupancy for Eighteen Compounds in Rats , 2009, Drug Metabolism and Disposition.

[94]  E. Acosta,et al.  Clinical pharmacodynamics of HIV-1 protease inhibitors: use of inhibitory quotients to optimise pharmacotherapy. , 2006, The Lancet. Infectious diseases.

[95]  Nahata Mc,et al.  Ceftriaxone: a third-generation cephalosporin. , 1985 .

[96]  B. Luxon,et al.  Albumin-mediated transport of rose bengal by perfused rat liver. Kinetics of the reaction at the cell surface. , 1983, The Journal of clinical investigation.

[97]  E. Burton,et al.  Plasma protein binding of celecoxib in mice, rat, rabbit, dog and human , 1999, Biopharmaceutics & drug disposition.

[98]  B. Meibohm,et al.  Pharmacokinetically-Guided Lead Optimization of Nitrofuranylamide Anti-Tuberculosis Agents , 2008, The AAPS Journal.

[99]  J. Schuhmacher,et al.  Determination of the free fraction and relative free fraction of drugs strongly bound to plasma proteins. , 2000, Journal of pharmaceutical sciences.

[100]  F. Zsila,et al.  Selective plasma protein binding of antimalarial drugs to alpha1-acid glycoprotein. , 2008, Bioorganic & medicinal chemistry.

[101]  K. Read,et al.  The relationship between sodium channel inhibition and anticonvulsant activity in a model of generalised seizure in the rat , 2009, Epilepsy Research.

[102]  D. Cocchetto,et al.  Protein Binding as a Primary Determinant of the Clinical Pharmacokinetic Properties of Non-Steroidal Anti-Inflammatory Drugs , 1987, Clinical pharmacokinetics.

[103]  K. Read,et al.  Receptor Occupancy and Brain Free Fraction , 2009, Drug Metabolism and Disposition.

[104]  E. Sellers.  Plasma protein displacement interactions are rarely of clinical significance. , 1979, Pharmacology.

[105]  P. Routledge,et al.  Diazepam and lidocaine plasma protein binding in renal disease , 1982, Clinical pharmacology and therapeutics.

[106]  A. Somogyi,et al.  Clinical Pharmacokinetics of Cimetidine , 1983, Clinical pharmacokinetics.

[107]  L. Kramer,et al.  Elevated Free Fractions of Valproic Acid in a Heart Transplant Patient with Hypoalbuminemia , 2000, The Annals of pharmacotherapy.

[108]  R. Haubrich,et al.  Phase I/II study of the toxicity, pharmacokinetics, and activity of the HIV protease inhibitor SC-52151. , 1997, Journal of acquired immune deficiency syndromes and human retrovirology : official publication of the International Retrovirology Association.

[109]  G. Scapin,et al.  (2S,3S)-3-Amino-4-(3,3-difluoropyrrolidin-1-yl)-N,N-dimethyl-4-oxo-2-(4-[1,2,4]triazolo[1,5-a]-pyridin-6-ylphenyl)butanamide: a selective alpha-amino amide dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes. , 2006, Journal of medicinal chemistry.

[110]  A. McLachlan,et al.  Changes in Tacrolimus Distribution in Blood and Plasma Protein Binding Following Liver Transplantation , 2004, Therapeutic drug monitoring.

[111]  D. Furst,et al.  Salicylate clearance, the resultant of protein binding and metabolism , 1979, Clinical pharmacology and therapeutics.

[112]  G R Wilkinson,et al.  Plasma binding and transport of diazepam across the blood-brain barrier. No evidence for in vivo enhanced dissociation. , 1989, The Journal of clinical investigation.

[113]  J. Gollan,et al.  Receptor for albumin on the liver cell surface may mediate uptake of fatty acids and other albumin-bound substances. , 1981, Science.

[114]  Manfred Kansy,et al.  Predicting plasma protein binding of drugs: a new approach. , 2002, Biochemical pharmacology.

[115]  T. Maurer,et al.  Use of Plasma and Brain Unbound Fractions to Assess the Extent of Brain Distribution of 34 Drugs: Comparison of Unbound Concentration Ratios to in Vivo P-Glycoprotein Efflux Ratios , 2007, Drug Metabolism and Disposition.

[116]  Y. Tagawa,et al.  Alpha 1-acid glycoprotein-binding as a factor in age-related changes in the pharmacokinetics of trimethoprim in piglets. , 1994, The Veterinary quarterly.

[117]  A. Dawidowicz,et al.  Anomalous relationship between free drug fraction and its total concentration in drug-protein systems II. Binding of different ligands to plasma proteins. , 2008, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[118]  Phil Jeffrey,et al.  Central Nervous System Drug Disposition: The Relationship between in Situ Brain Permeability and Brain Free Fraction , 2007, Journal of Pharmacology and Experimental Therapeutics.

[119]  M. Nöldner,et al.  KA-672 inhibits rat brain acetylcholinesterase in vitro but not in vivo , 1999, Neuroscience Letters.

[120]  L. Benet,et al.  Changes in plasma protein binding have little clinical relevance , 2002, Clinical pharmacology and therapeutics.

[121]  Z H Israili,et al.  HUMAN ALPHA-1-GLYCOPROTEIN AND ITS INTERACTIONS WITH DRUGS†,‡ , 2001, Drug metabolism reviews.

[122]  T. Maurer,et al.  RELATIONSHIP BETWEEN EXPOSURE AND NONSPECIFIC BINDING OF THIRTY-THREE CENTRAL NERVOUS SYSTEM DRUGS IN MICE , 2005, Drug Metabolism and Disposition.

[123]  C. Tschanz,et al.  Importance of radiochemical purity of radiolabeled drugs used for determining plasma protein binding of drugs. , 1981, Journal of pharmaceutical sciences.

[124]  E. Sausville,et al.  Unpredicted clinical pharmacology of UCN-01 caused by specific binding to human alpha1-acid glycoprotein. , 1998, Cancer research.

[125]  B. Debaene,et al.  Steady-state trough serum and epithelial lining fluid concentrations of teicoplanin 12 mg/kg per day in patients with ventilator-associated pneumonia , 2006, Intensive Care Medicine.

[126]  V. Miller,et al.  Protein binding in antiretroviral therapies. , 2003, AIDS research and human retroviruses.

[127]  L. Shaw,et al.  Factors affecting the binding of disopyramide to serum proteins. , 1985, Clinical chemistry.

[128]  P. Lam,et al.  Discovery of 1-[3-(aminomethyl)phenyl]-N-3-fluoro-2'-(methylsulfonyl)-[1,1'-biphenyl]-4-yl]-3-(trifluoromethyl)-1H-pyrazole-5-carboxamide (DPC423), a highly potent, selective, and orally bioavailable inhibitor of blood coagulation factor Xa. , 2001, Journal of medicinal chemistry.

[129]  P. LoRusso,et al.  Implications of Plasma Protein Binding for Pharmacokinetics and Pharmacodynamics of the γ-Secretase Inhibitor RO4929097 , 2012, Clinical Cancer Research.

[130]  D. Bourke,et al.  An interaction between aspirin and valproate: the relevance of plasma protein displacement drug-drug interactions. , 2006, The American journal of psychiatry.

[131]  Rikiya Ohashi,et al.  Effect of Plasma Protein Binding on in Vitro-in Vivo Correlation of Biliary Excretion of Drugs Evaluated by Sandwich-Cultured Rat Hepatocytes , 2008, Drug Metabolism and Disposition.

[132]  S. Hall,et al.  Plasma protein binding of flurbiprofen: enantioselectivity and influence of pathophysiological status. , 1989, The Journal of pharmacology and experimental therapeutics.

[133]  C. Kloft,et al.  Pharmacokinetics of Unbound Linezolid in Plasma and Tissue Interstitium of Critically Ill Patients after Multiple Dosing Using Microdialysis , 2006, Antimicrobial Agents and Chemotherapy.

[134]  A. Karim.  Inverse Nonlinear Pharmacokinetics of Total and Protein Unbound Drug (Oxaprozin): Clinical and Pharmacokinetic Implications , 1996, Journal of clinical pharmacology.

[135]  Yuichi Sugiyama,et al.  Which concentration of the inhibitor should be used to predict in vivo drug interactions from in vitro data? , 2002, AAPS PharmSci.

[136]  S. Arbuck,et al.  Interspecies differences in in vitro etoposide plasma protein binding. , 1991, Biochemical pharmacology.

[137]  T. Kamimura,et al.  Effect of protein binding in serum on therapeutic efficacy of cephem antibiotics , 1992, Antimicrobial Agents and Chemotherapy.

[138]  F. Akhlaghi,et al.  Distribution of Cyclosporin in Organ Transplant Recipients , 2002, Clinical pharmacokinetics.

[139]  A. Schweitzer,et al.  Biodistribution and Plasma Protein Binding of Zoledronic Acid , 2008, Drug Metabolism and Disposition.

[140]  A. Dasgupta.  Usefulness of monitoring free (unbound) concentrations of therapeutic drugs in patient management. , 2007, Clinica chimica acta; international journal of clinical chemistry.

[141]  Ulf Bredberg,et al.  Improved Measurement of Drug Exposure in the Brain Using Drug-Specific Correction for Residual Blood , 2010, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[142]  Some features of the kinetics and equilibrium of drug binding to plasma proteins , 2008 .

[143]  J. Lin,et al.  Nonlinear kinetics of alendronate. Plasma protein binding and bone uptake. , 1994, Drug metabolism and disposition: the biological fate of chemicals.

[144]  H. Tanaka,et al.  Drug-protein binding and blood-brain barrier permeability. , 1999, The Journal of pharmacology and experimental therapeutics.

[145]  Jiunn H. Lin,et al.  Tissue distribution and pharmacodynamics: a complicated relationship. , 2006, Current drug metabolism.

[146]  J. Martyn,et al.  Systemic Inflammation Leads to Resistance to Atracurium without Increasing Membrane Expression of Acetylcholine Receptors , 2003, Anesthesiology.

[147]  Chen Lihua,et al.  Discovery of γ-Lactam Hydroxamic Acids as Selective Inhibitors of Tumor Necrosis Factor α Converting Enzyme: Design, Synthesis, and Structure−Activity Relationships , 2002 .

[148]  J. Johnson,et al.  Influence of race or ethnicity on pharmacokinetics of drugs. , 1997, Journal of pharmaceutical sciences.

[149]  P. Gozzi,et al.  Serum protein binding of tolterodine and its major metabolites in humans and several animal species , 1999, Biopharmaceutics & drug disposition.

[150]  Derek Leishman,et al.  Towards a drug concentration effect relationship for QT prolongation and torsades de pointes. , 2002, Current opinion in drug discovery & development.

[151]  B. Baguley,et al.  Effects of protein binding on the in vitro activity of antitumour acridine derivatives and related anticancer drugs , 2000, Cancer Chemotherapy and Pharmacology.

[152]  M. L. Howard,et al.  Plasma protein binding in drug discovery and development. , 2010, Combinatorial chemistry & high throughput screening.

[153]  K. Korzekwa,et al.  Impact of pH on plasma protein binding in equilibrium dialysis. , 2008, Molecular pharmaceutics.

[154]  A. Dawidowicz,et al.  Anomalous relationship between free drug fraction and its total concentration in drug-protein systems I. Investigation of propofol binding in model HSA solution. , 2008, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[155]  Y. Sawada,et al.  Dose-dependent hepatic handling of l-propranolol determined by multiple indicator dilution method: influence of tissue binding of l-propranolol on its hepatic elimination. , 1993, Biological and Pharmaceutical Bulletin.

[156]  D. Chadwick.  Concentration-Effect Relationships of Valproic Acid , 1985, Clinical pharmacokinetics.

[157]  C. Kilpatrick,et al.  Intra-dose variation in plasma protein binding of sodium valproate in epileptic patients. , 1982, British journal of clinical pharmacology.

[158]  I. Mahmood.  Interspecies Scaling: Role of Protein Binding in the Prediction of Clearance from Animals to Humans , 2000, Journal of clinical pharmacology.